The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
The Royal Melbourne Hospital · Victorian Infectious Diseases Reference Laboratory · +4 more institutions
Abstract
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
Citation impact
- FWCI
- 53.72
- Percentile
- 100%
- References
- 30
Authors
5- LCLeon Caly
The Royal Melbourne Hospital, Victorian Infectious Diseases Reference Laboratory, Peter Doherty Institute
- JDJulian Druce
The Royal Melbourne Hospital, Victorian Infectious Diseases Reference Laboratory, Peter Doherty Institute
- MCMike Catton
The Royal Melbourne Hospital, Victorian Infectious Diseases Reference Laboratory, Peter Doherty Institute
- DADavid A. Jans
Australian Regenerative Medicine Institute, Monash University
- KMKylie M. WagstaffCorresponding
Discovery Institute, Australian Regenerative Medicine Institute, Monash University
Topics & keywords
- Ivermectin
- Virology
- Vero cell
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Drug
- Medicine
- Clinical trial
- Outbreak
- Good health and well-being